Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors
by
, , , , , , , and
Anne Menz
1,
Nora Lony
1,
Maximilian Lennartz
1,
Sebastian Dwertmann Rico
1,
Ria Schlichter
1,
Simon Kind
1,
Viktor Reiswich
1,
Florian Viehweger
1,
David Dum
1,
Andreas M. Luebke
1,
Martina Kluth
1,
Natalia Gorbokon
1,
Claudia Hube-Magg
1,
Christian Bernreuther
1,
Ronald Simon
1,*,
Till S. Clauditz
1,
Guido Sauter
1,
Andrea Hinsch
1,
Frank Jacobsen
1,
Andreas H. Marx
2,
Stefan Steurer
1,
Sarah Minner
1,
Eike Burandt
1,
Till Krech
1,3,
Patrick Lebok
1,3 and
Sören Weidemann
1add
Show full author list
1
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
2
Department of Pathology, Academic Hospital Fuerth, 90766 Fuerth, Germany
3
Institute of Pathology, Clinical Center Osnabrueck, 49076 Osnabrueck, Germany
*
Author to whom correspondence should be addressed.
Diagnostics 2024, 14(10), 1044; https://doi.org/10.3390/diagnostics14101044
Submission received: 2 April 2024
/
Revised: 26 April 2024
/
Accepted: 30 April 2024
/
Published: 17 May 2024
(This article belongs to the Section Pathology and Molecular Diagnostics)
Abstract
:EpCAM is expressed in many epithelial tumors and is used for the distinction of malignant mesotheliomas from adenocarcinomas and as a surrogate pan-epithelial marker. A tissue microarray containing 14,832 samples from 120 different tumor categories was analyzed by immunohistochemistry. EpCAM staining was compared with TROP2 and CKpan. EpCAM staining was detectable in 99 tumor categories. Among 78 epithelial tumor types, the EpCAM positivity rate was ≥90% in 60 categories—including adenocarcinomas, neuroendocrine neoplasms, and germ cell tumors. EpCAM staining was the lowest in hepatocellular carcinomas, adrenocortical tumors, renal cell neoplasms, and in poorly differentiated carcinomas. A comparison of EpCAM and CKpan staining identified a high concordance but EpCAM was higher in testicular seminomas and neuroendocrine neoplasms and CKpan in hepatocellular carcinomas, mesotheliomas, and poorly differentiated non-neuroendocrine tumors. A comparison of EpCAM and TROP2 revealed a higher rate of TROP2 positivity in squamous cell carcinomas and lower rates in many gastrointestinal adenocarcinomas, testicular germ cell tumors, neuroendocrine neoplasms, and renal cell tumors. These data confirm EpCAM as a surrogate epithelial marker for adenocarcinomas and its diagnostic utility for the distinction of malignant mesotheliomas. In comparison to CKpan and TROP2 antibodies, EpCAM staining is particularly common in seminomas and in neuroendocrine neoplasms.
1. Introduction
Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein which was initially considered and termed a cell adhesion molecule, although it has only weak cell-adhesive properties [1,2]. EpCAM acts as a multi-functional transmembrane protein involved in the regulation of cell adhesion, proliferation, migration, stemness, and epithelial-to-mesenchymal transition (EMT) of normal and neoplastic epithelial cells (summarized in [3,4]). Inter- and intracellular EpCAM signaling mechanisms involve the generation of functionally active fragments that are shed to the extra- and intracellular space. EpCAM and its fragments interact with various proteins including claudins, CD44, and E-cadherin, and regulate growths relevant proteins such as c-Myc, Cyclin A, E, and D1 (summarized in [3,4]).
EpCAM expression has been investigated in a broad range of epithelial neoplasms and its expression levels were found to have a prognostic impact in many tumor types (summarized in [3,5]). Due to its membranous expression in epithelial tumors, EpCAM represents a candidate for targeted cancer therapies and various EpCAM directed monoclonal antibodies have been investigated in clinical phase I/II studies (summarized in [3]). In diagnostic surgical pathology, EpCAM immunohistochemistry (IHC) is employed for the distinction of malignant mesothelioma from primary lung cancer (summarized in [6]) and—due to its broad expression in epithelial neoplasms—as a surrogate pan-epithelial marker for the detection of circulating tumor cells (summarized in [7]).
Although more than 1000 studies have investigated EpCAM immunostaining at least in common tumor types (PubMed, 12 September 2023), EpCAM has not or has only rarely been investigated in many other tumor entities. Furthermore, the results of the various studies are often inconsistent, especially for the most commonly studied tumor types. For example, the reported positivity ranges between 0% and 100% in hepatocellular carcinoma [8,9], lobular breast cancers [8,10], squamous cell carcinoma of the esophagus ([10,11], and of the cervix [10,11]], 0–54% in epithelioid mesothelioma [12,13,14], 17–100% in breast cancers of no special type [11,15], or 51–100% in adenocarcinoma of the lung [16,17,18]. Obviously, technical aspects such as different antibodies and staining protocols as well as different scoring criteria have contributed to these differences, making a comprehensive and standardized analysis of EpCAM expression in different human tumor types highly desirable.
Accordingly, the principle aim of our study was to evaluate EpCAM in human tumors to better comprehend the range of diagnostic applications of EpCAM IHC. For this purpose, more than 14,000 tissue samples from 120 different tumor types and subtypes and 76 non-neoplastic tissues were evaluated for EpCAM protein expression by IHC in a tissue microarray (TMA) format. The same tissue cohort has been studied for immunohistochemical expression of trophoblast cell surface glycoprotein 2 (TROP2) and pan-cytokeratin antibodies (CKpan) before [19,20]. TROP2, also known as tumor-associated calcium signal transducer 2 (TACSTD2), is another druggable membrane glycoprotein which is closely related to EpCAM and has also been shown to occur in many epithelial tumors but not in malignant mesotheliomas (summarized in [19,21]). CKpan markers represent the gold standard for the detection of epithelial cells [22]. In the light of the existing data, it also appeared attractive to us to systematically compare the staining patterns of EpCAM, TROP2, and CKpan antibodies.
2. Materials and Methods
2.1. Tissue Microarrays (TMAs)
The normal tissue TMA contained 8 samples from 8 different donors for each of 76 different normal tissue types (608 samples on one slide). The cancer TMAs included 14,832 tumor samples from 120 tumor types and subtypes distributed across 52 TMA slides. All cancer samples were obtained from primary tumors. Histopathological data on grade, pT or pN status, and molecular data on HER2, the progesterone receptor (PR), and the estrogen receptor (ER) were available from subsets of breast (n = 1475), urothelial (1073), and renal carcinomas (n = 1157), as well as of 902 squamous cell carcinomas of different sites of origin. Clinical follow-up data were available from 877 breast, 254 bladder, and 850 kidney cancer patients with a median follow-up time of 43/14/39 months (range 1–88; 1–77; 1–250 months). The composition of the TMAs is described in detail in the Results Section. From previous studies, data on CKpan were available for 13,501 and for TROP2 in 16,024 cases [19,20]. All samples were from the archives of the Institutes of Pathology, University Hospital of Hamburg, Germany, the Institute of Pathology, Clinical Center Osnabrueck, Germany, and the Department of Pathology, Academic Hospital Fuerth, Germany, collected between 2005 and 2020. Tissues were fixed in 4% buffered formalin and then embedded in paraffin. TMA manufacturing was described earlier in detail [23,24]. In brief, one tissue spot (diameter: 0.6 mm) was transmitted from a cancer-containing donor block in an empty recipient paraffin block. The use of archived remnants of diagnostic tissues for the manufacturing of TMAs and their analysis for research purposes as well as patient data analysis without informed patient consent is covered by local laws (HmbKHG, §12) and by the local ethics committee (Ethics Commission Hamburg, WF-049/09). All work has been carried out in compliance with the Helsinki Declaration.
2.2. Immunohistochemistry (IHC)
Freshly prepared TMA sections were immunostained on one day in one experiment. Slides were deparaffinized with xylol, rehydrated through a graded alcohol series, and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 7.8 Tris-EDTA buffer. Endogenous peroxidase activity was blocked with Dako Peroxidase Blocking Solution™ (Agilent, Santa Clara, CA, USA; #52023) for 10 min. Primary antibody specific against the EpCAM protein (rabbit recombinant, MSVA-326R, MS Validated Antibodies, Hamburg, Germany, 2315-326R, epitope not disclosed by the manufacturer) was applied at 37 °C for 60 min at a dilution of 1:150. Bound antibody was then visualized using the EnVision Kit™ (Agilent, Santa Clara, CA, USA; #K5007) according to the manufacturer’s directions. The sections were counterstained with haemalaun. Staining was predominantly membranous and sometimes accompanied by cytoplasmic positivity. For normal tissue analysis, the staining intensity in the different cell types was recorded as negative (0, no staining), weak (1+ staining intensity), moderate (2+ staining intensity), or strong (3+ staining intensity). Scoring of the staining in tumor tissues was performed according to a standard procedure [25]. In brief, raw data were collected including the percentage of EpCAM-positive tumor cells (estimated) and the staining intensity in a semi-quantitative scale semi-quantitatively (0, 1+, 2+, 3+). The raw data were then used to define the staining results in four groups as follows: negative: no staining at all; weak staining: staining intensity of 1+ in ≤70% or staining intensity of 2+ in ≤30% of tumor cells; moderate staining: staining intensity of 1+ in >70%, staining intensity of 2+ in >30% but in ≤70% or staining intensity of 3+ in ≤30% of tumor cells; strong staining: staining intensity of 2+ in >70% or staining intensity of 3+ in >30% of tumor cells. For the purpose of antibody validation, the normal tissue TMA was also analyzed for EpCAM expression by using the monoclonal mouse anti-EpCAM antibody BER-Ep4 (Agilent, Santa Clara, CA, USA; #IR637, ready to use, pH 6.0, epitope not disclosed by the manufacturer) in the Autostainer Link 48 (Agilent, Santa Clara, CA, USA) according to the manufacturer’s directions. Examples of tumors with different scores are shown in Supplementary Figure S1.
2.3. Statistics
Statistical calculations were performed with JMP 16 software (SAS Insitute Inc., NC, USA). Contingency tables and the chi2-test were performed to search for associations between EpCAM immunostaining and tumor phenotype of selected tumor types/subtypes. Survival curves were calculated according to Kaplan–Meier. The log-rank test was applied to detect significant differences between groups. A p-value of ≤0.05 was considered as statistically significant.
3. Results
3.1. Technical Issues
A total of 12,780 (86.2%) of 14,832 tumor samples and at least 4 tissue samples per normal tissue category were interpretable in our TMA analysis. Non-interpretable samples demonstrated a lack of unequivocal tumor cells or an absence of tissue in the respective TMA spots.
3.2. EpCAM in Normal Tissues
Using MSVA-326R, EpCAM immunostaining was found to be strong in all epithelial cells of the gastrointestinal tract (strongest staining of neuroendocrine cells; lowest staining of parietal cells of the stomach, where staining was limited to the basolateral membranes), all epithelial cells of the gallbladder and bile ducts, pancreas, salivary glands, Brunner glands, prostate, seminal vesicle, epididymis, respiratory epithelium (lowest staining in the basal cell layers), lung, endocervix, endometrium, fallopian tube, thyroid, parathyroid, and the adenohypophysis. In squamous epithelium, EpCAM staining was generally weak and not always seen. If present, EpCAM was most strongly expressed in the basal cell layers but expression also expanded to the upper third in some samples. Some squamous epithelia only showed few scattered EpCAM-positive cells of the upper cell layers. In the skin, EpCAM was expressed in peripheral germinative cells of sebaceous glands, eccrine glands, and in root sheaths of hair follicles but not in the epidermis. Scattered squamous epithelial cells in tonsil crypts showed a strong staining. Most thymus epithelial cells including corpuscles of Hassall’s showed a weak to moderate EpCAM positivity. Urothelium stained strongly, but sometimes less intensely in umbrella cells. In the kidney, strong staining was seen in the distal tubuli, while staining was less intense and focused to the basolateral membranes in the proximal tubuli. Scattered epithelial cells lining the Bowman capsule were also positive. In the breast glands, luminal cells were strongly positive but myoepithelial cells showed much less or absent staining. In the testis, spermatogonia and spermatocytes stained moderately or strongly but Sertoli and Leydig cells were negative. In the adrenal gland, a faint to moderate membranous staining of adrenocortical cells was occasionally seen. In the placenta, staining was weak to moderate in the cytotrophoblast, faint in the amnion, and moderate in chorion cells. Representative images are shown in Figure 1, and all results of the normal tissues’ analysis are listed in Supplementary Table S1. EpCAM staining was absent in hepatocytes, aorta and other blood vessels, muscle, fat, lymph node, spleen, neurohypophysis, and the brain. All cell types found to be EpCAM-positive by MSVA-326R were also positive by using Ber-EP4, although the Ber-EP4 staining was found to be considerably weaker (Supplementary Figure S2).
EpCAM in cancer. A predominantly membranous EpCAM immunostaining was detectable in 10,513 (82.3%) of the 12,780 analyzable tumors, including 1010 (7.9%) with weak, 1993 (15.6%) with moderate, and 7510 (58.8%) with strong immunostaining. Overall, 99 (82.5%) of 120 tumor categories showed detectable EpCAM expression and 85 (70.8%) tumor categories contained at least one case with strong positivity (Table 1). Among 78 epithelial tumor categories, the EpCAM positivity rate was ≥99% in 46 (59.0%) and 90.0% to 98.9% in 14 categories (17.9%). Tumor categories with particularly high positivity rates included adenocarcinomas and neuroendocrine neoplasms (including small cell carcinomas), as well as germ cell tumors. The total rate of positivity and the fraction of strongly positive tumors tended to be lower in urothelial neoplasms and in squamous cell carcinomas. Among epithelial neoplasms, the lowest rates of positive and strongly positive cases occurred in hepatocellular carcinomas, adrenocortical tumors, renal cell neoplasms, and in carcinomas with a particularly poor differentiation such as sarcomatoid urothelial carcinomas and anaplastic carcinomas of the thyroid. EpCAM positivity was seen in 16.7% of 24 epithelioid and in 30.2% of 53 biphasic malignant mesotheliomas where tumor cell staining was always limited to epithelioid cells. In contrast, EpCAM positivity was seen in 100% of 147 adenocarcinomas of the lung. It is of note that some EpCAM positivity could also be observed in several mesenchymal and hematological neoplasms. Representative images of EpCAM-positive tumors are shown in Figure 2. A ranking order of EpCAM-positive cancers is given in Figure 3. The relationships between EpCAM staining and histopathological or molecular features in breast, urothelial, and renal tumors, and squamous cell carcinomas of different sites are shown in Table 2 and Supplementary Table S3. High EpCAM staining was linked to high grade (p < 0.0001), distant metastasis (p = 0.0006), ER/PR loss (p < 0.0001 each), and HER2 positivity (p = 0.0009) in breast cancer of no special type, as well as to high grade and to HPV infection in squamous cell carcinomas of different sites (p < 0.0001 each; Table 2 and Supplementary Table S3). Low EpCAM staining was linked to invasive disease in urothelial carcinoma (p < 0.0001) and to high grade in clear cell renal cell carcinomas (p < 0.05). Significant associations with overall survival and recurrence free survival were not seen in breast, urothelial, and clear cell renal carcinomas (Supplementary Figure S3).
EpCAM vs. CKpan in cancer. Data on both EpCAM and CKpan immunostaining were available for 11,053 tumors from 101 tumor categories. Their comparison resulted in a generally high concordance, especially in adenocarcinomas where both EpCAM and CKpan were positive in almost 100% of cases (Supplementary Figure S4). The positivity rate was higher for EpCAM (100%) than for CKpan (23.2%; p < 0.0001) in testicular seminomas and—less markedly—in several neuroendocrine neoplasms. The positivity rate was lower for EpCAM in mesotheliomas, hepatocellular carcinomas, very poorly differentiated tumors (anaplastic thyroid cancer, sarcomatoid urothelial cancer), and—to a lesser extent—in squamous cell carcinomas. A positivity for both markers was very rarely seen in hematologic or mesenchymal tumors.
EpCAM vs. TROP2 (EpCAM2) in cancer. Both EpCAM and TROP2 immunostaining data were available for 10,998 tumors from 101 tumor categories. Although many epithelial neoplasms stained with both antibodies, the fraction of positive cases was often lower for TROP2 than for EpCAM (Supplementary Figure S5). Squamous cell carcinomas of different sites of origin made up for most tumor categories with a higher rate of TROP2 positivity than seen for EpCAM. The rate of TROP2 positivity was markedly lower than for EpCAM in testicular germ cell tumors, neuroendocrine neoplasms, renal cell tumors, and also in many gastrointestinal adenocarcinomas. In hepatocellular carcinomas, 15.4% were positive for EpCAM alone, 15.4% were positive for TROP2 alone, and only 2.6% for both EpCAM and TROP2. In epithelioid mesotheliomas, 9.1% were positive for EpCAM alone, 13.6% were positive for TROP2 alone, and only 4.5% for both EpCAM and TROP2. A compilation of EpCAM, TROP2, and CKpan is given in Supplementary Figure S6.
4. Discussion
Our standardized analysis of 14,832 tumors provides a comprehensive overview on EpCAM immunostaining in malignant tumors. That the graphical representation of the frequencies of EpCAM expression among different tumor categories resulted in an S-shaped curve reflects the intense EpCAM immunostaining in the vast majority of epithelial neoplasms. The validity of our data is supported by the fact that non-epithelial tumors were most commonly EpCAM-negative as described before [26].
The comparison with CKpan revealed a generally high concordance with EpCAM staining, especially in adenocarcinomas where both markers were positive in almost 100% of cases. This justifies the widespread use of anti-EpCAM antibodies for the detection of circulating tumor cells in these tumor categories (summarized in [7]). The rate of EpCAM positivity was especially lower than of CKpan staining in hepatocellular carcinomas, mesotheliomas, squamous cell carcinomas, and in very poorly differentiated tumors such as anaplastic cancers of the thyroid or sarcomatoid urothelial carcinomas. The particularly low rate of EpCAM positivity in mesotheliomas (26%), hepatocellular carcinomas (14.3%), and squamous cell carcinomas of various sites of origin (59.0–98.3%, mean 84.0%) is in the lower range of previous studies describing EpCAM positivity on average in 32% of hepatocellular carcinomas, and somewhat higher compared to previous studies describing EpCAM positivity on average in 10% of mesotheliomas and 66% of squamous cell carcinomas (Supplementary Table S2). EpCAM has therefore been suggested as a tool for the distinction of hepatocellular carcinomas and malignant mesotheliomas from their differential diagnoses [11]. The lower positivity rate of EpCAM as compared to CKpan in squamous cell carcinomas obviously reflects the rather low level of EpCAM expression in normal squamous epithelium, while CKpan staining is usually strong in these tissues [20]. That the rate of EpCAM positivity was somewhat lower than that of CKpan positivity in very poorly differentiated epithelial tumors may be reflective of the higher likelihood of a tumor cell losing the expression of just one protein (EpCAM) as compared to simultaneously abandoning the expression of multiple different intermediate filaments in case of cellular dedifferentiation accompanying tumor development and progression.
The markedly higher rate of EpCAM staining as compared to CKpan in seminoma is consistent with data from Schönberger et al. [27] describing EpCAM positivity in nearly all of 32 analyzed malignant germ cell neoplasms including 7 seminomas. Based on these findings, EpCAM is under evaluation as a therapeutic target in germ cell tumors [28] and has been used to identify circulating germ cell tumor cells in the blood [29]. That EpCAM positivity was more common in several neuroendocrine neoplasms than CKpan positivity fits well with the particularly high EpCAM expression in normal neuroendocrine cells in the gastrointestinal tract. The specific role of EpCAM in normal and neoplastic neuroendocrine cells is unclear, although Cives et al. [30] recently provided evidence for a role of EpCAM in EMT in neuroendocrine tumors.
The comparison with TROP2 revealed that EpCAM is less commonly expressed in squamous cell carcinomas but more abundant in most other epithelial neoplasms especially in germ cell tumors, neuroendocrine neoplasms, renal cell tumors, and in gastrointestinal adenocarcinomas. These findings mirror the findings in normal tissues where—in contrast to what is seen for EpCAM—TROP2 positivity is rare in the normal gastrointestinal tract, absent in the testis, inconspicuous in neuroendocrine cells, and absent in the proximal tubuli of the kidney, while high levels of TROP2 are common in squamous epithelium [19]. The lower prevalence of TROP2 expression in normal and neoplastic epithelial cells shows that TROP2 may not replace EpCAM as a surrogate epithelial marker. However, the comparable but independent staining pattern of both markers in malignant mesothelioma, adenocarcinoma, and squamous cell carcinoma of the lung may suggest that TROP2 may complement the list of biomarkers that are most commonly used for this purpose such as calretinin, WT1, D2-40, cytokeratin 5/6, TTF-1, CEA, EpCAM, and Napsin A [31].
The evaluation of EpCAM expression in the context of clinicopathological and molecular features demonstrated that—depending on the tumor type—both upregulation and reduced expression of EpCAM can be associated with unfavorable tumor features and tumor progression. The strong link between poor differentiation and high EpCAM expression in squamous cell carcinomas from different sites of origin may suggest a role of EpCAM upregulation for the progression of these tumors. In line with these findings, other authors have previously described associations between elevated EpCAM levels and a poor prognosis in squamous cell carcinomas of the head and neck [32,33], the glottis [33], and the esophagus [34,35]. The significant association of high EpCAM levels with positive HPV status argues for a dependence of the EpCAM function and expression on the status of specific molecular pathways in cancer cells. The HPV E6/E7 oncoproteins affect numerous intracellular signaling pathways such as ERK, JAK, YY1, API, NF-kB, AKT, and WNT [36], whose key proteins (including E-cadherin, EGFR, c-Myc, and cyclins A, E, and D1) interact with EpCAM [3,4]. In breast cancer, elevated EpCAM expression was also tightly linked to key molecular features such as the loss of ER and PR expression as well as HER2 overexpression in our study. Soysal et al. described similar findings in a cohort of 1365 breast cancers and found that the prognostic impact of EpCAM expression depended on the molecular subtype [37]. The significant associations between low EpCAM expression and high tumor grade in clear cell renal cell carcinoma and invasive tumor growth in urothelial carcinoma demonstrates that tumor progression can also go along with EpCAM downregulation. Comparable results have previously been described by several authors both in clear cell renal cell carcinomas [38,39,40,41] and in urothelial neoplasms [42]. It is of note that other authors had described reciprocal results and found associations between high-level EpCAM expression and tumor progression in renal cell [43] or between low EpCAM expression and tumor progression in squamous cell carcinomas [44]. These discrepant results are reflective of highly variable results described for the prevalence of EpCAM expression ranging from <20% to >80% in many cancer categories (literature summarized in Figure 4). These discrepancies are likely to be due to the use of different antibodies, staining protocols, and criteria for defining positive cancers.
Considering the large scale of our project, emphasis was placed on a thorough validation of our EpCAM assay. The International Working Group for Antibody Validation (IWGAV) has proposed that antibody validation for IHC on formalin-fixed tissues should include either a comparison of the findings obtained by two different independent antibodies or a comparison with expression data obtained by another independent method [45]. To ensure as much as possible that any antibody cross-reactivity would be detected, 76 different normal tissue categories were employed for our validation experiment. The specificity of our EpCAM assay was supported by the good concordance of MSVA-326R staining with RNA data obtained from three independent RNA screening studies [46,47,48,49]. MSVA-326R staining was almost exclusively seen in organs with documented RNA expression and its staining intensity was the strongest in tissues with the highest RNA levels such as the intestine, thyroid, and parathyroid glands and low in the adrenal gland, a tissue with particularly low EpCAM RNA expression. EpCAM staining by MSVA-326R staining in tissues without documented EpCAM RNA expression such as the liver, placenta, and the thymus was confirmed by comparison with the independent EpCAM antibody Ber-EP4 (Agilent, #IR637, RTU). This comparison also confirmed all specific EpCAM-positive cell types identified by MSVA-326R although the staining intensity obtained by the Ber-EP4 RTU resulted in a considerably weaker staining (Supplementary Figure S2). We assume that these differences in staining intensity are due to the too-low sensitivity of our Ber-EP4 assay, because MSVA-326R but not BER-EP4 resulted in a significant staining of proximal tubuli in the kidney. At least a moderate intensity of basolateral EpCAM staining in the majority of proximal tubules cells has been suggested as the optimal positive tissue control by NordiQC, a major organization devoted to quality control in IHC (https://www.nordiqc.org/epitope.php?id=44 accessed on 10 October 2023).
5. Conclusions
In summary, our data provide a comprehensive overview on EpCAM expression in cancer and confirm the suitability of EpCAM as a surrogate epithelial marker for adenocarcinomas and its diagnostic utility for the distinction of malignant mesotheliomas from pulmonary adenocarcinoma. They also show that—dependent on the tumor type—both upregulation and downregulation of EpCAM can be related to cancer progression. The comparison with CKpan revealed that EpCAM staining is particularly common in seminomas and in neuroendocrine neoplasms, while TROP2 is more commonly expressed in squamous cell carcinomas.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics14101044/s1, Supplementary Figure S1. Examples of tumors with different scores of EpCAM expression. (A)–(C): No detectable staining (negative) in cases of (A) carcinosarcoma of the ovary, (B) gastrointestinal stromal tumor, and (C) muscle invasive urothelial carcinoma; (D)–(F): Weak staining in 2 cases of (D)–(E) seminoma, and (F) muscle invasive urothelial carcinoma; (G)–(I) moderate staining in 3 cases of muscle invasive urothelial carcinomas; and (J)–(L) strong staining in 3 cases of cholangiocarcinomas. Supplementary Figure S2. IHC validation by comparison of antibodies. The panels show a concordance of immunostaining results obtained by two independent EpCAM antibodies (MSVA-326R, BerEP4). Using MSVA-326R, a predominantly membranous positivity was seen at variable intensity in epithelial cells of the stomach (A), pneumocytes of the lung (B), urothelial cells (C), epithelial cells of the thymus (D), a fraction of squamous epithelial cells of tonsil crypts (E), basal cells of squamous epithelium of the uterine cervix (F), cytotrophoblast cells (G) and amnion cells (H) of the placenta, a fraction of adrenocortical cells (I), as well as in spermatogonia and spermatocytes of the testis (K). Using clone BerEP4 (RTU), staining was considerably weaker but stained identical cell types in the stomach (L), lung (M), urothelium (N), thymus (O), squamous epithelial cells of tonsil crypts (P), squamous epithelium of the uterine cervix (Q), cytotrophoblast (R) and amnion (S) of the placenta, adrenal gland (T), and the testis (U). In the kidney, EpCAM staining was strong in distal tubuli and weak to moderate (predominantly basolateral) by MSVA-326R (V), while staining by BerEP4 was limited to distal tubuli (W). The images A-K/V and M-U/W are from consecutive tissue sections. Supplementary Figure S3. EpCAM immunostaining and prognosis. The panel shows Kaplan–Meier plots for EpCAM immunostaining intensity and overall survival (top left) as well as recurrence-free survival (top right) of patients with muscle invasive urinary bladder cancer, overall survival (middle left) as well as recurrence-free survival (middle right) of patients with clear cell renal cell cancer, and overall survival of patients with breast cancers of no special type (bottom). Supplementary Figure S4. Combined immunostaining of EpCAM and CKpan in human tumors. The bar charts show the fractions of tumors with co-expression of EpCAM and CKpan (yellow), tumors with EpCAM expression alone (red), and tumors with CKpan expression alone (green) in individual tumor types that have been grouped according to the organ system of origin. Supplementary Figure S5. Combined immunostaining of EpCAM and TROP2 in human tumors. The bar charts show the fractions of tumors with co-expression of EpCAM and TROP2 (yellow), tumors with EpCAM expression alone (red), and tumors with TROP2 expression alone (green) in individual tumor types that have been grouped according to the organ system of origin. Supplementary Figure S6. Combined immunostaining of EpCAM, TROP2, and CKpan in human tumors. The bar charts show the fractions of tumors according to the co-expression patterns of EpCAM, TROP2, and CKpan in individual tumor types that have been grouped according to the organ system of origin. Supplementary Table S1. Summary of EpCAM staining in normal tissues. Supplementary Table S2. Summary of previous EpCAM immunohistochemical studies. Supplementary Table S3. EpCAM immunostaining and HPV status in squamous cell carcinomas of different sites of origin.
Author Contributions
A.M., N.L., S.W., R.S. (Ronald Simon), M.K., G.S.: contributed to conception, design, data collection, data analysis, and manuscript writing. A.M., N.L., M.L., S.D.R., R.S. (Ria Schlichter), S.K., V.R., F.V., D.D., A.M.L., N.G., C.B., T.S.C., A.H., F.J., A.H.M., S.S., S.M., E.B., T.K., P.L.: participated in pathology data analysis, data interpretation, and collection of samples. R.S. (Ronald Simon), M.K., C.H.-M.: data analysis. A.M., R.S. (Ronald Simon), G.S.: study supervision. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The usage of archived diagnostic left-over tissues for manufacturing of TMAs and their analysis for research purposes as well as patient data analysis has been approved by local laws (HmbKHG, §12.1) and by the local ethics committee (Ethics Commission Hamburg, WF-049/09). All work has been carried out in compliance with the Helsinki Declaration.
Informed Consent Statement
Patient consent was waived due to local laws (HmbKHG, §12.1) that permit research with anonymized diagnostic left-over tissue samples.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors on request.
Acknowledgments
We are grateful to Melanie Steurer, Inge Brandt, Maren Eisenberg, and Sünje Seekamp for excellent technical assistance.
Conflicts of Interest
The monoclonal rabbit EpCAM antibody, clone MSVA-326R was provided from MS Validated Antibodies GmbH (owned by a family member of G.S.).
References
- Koprowski, H.; Steplewski, Z.; Mitchell, K.; Herlyn, M.; Herlyn, D.; Fuhrer, P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979, 5, 957–971. [Google Scholar] [CrossRef] [PubMed]
- Litvinov, S.V.; Balzar, M.; Winter, M.J.; Bakker, H.A.; Briaire-de Bruijn, I.H.; Prins, F.; Fleuren, G.J.; Warnaar, S.O. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J. Cell Biol. 1997, 139, 1337–1348. [Google Scholar] [CrossRef] [PubMed]
- Eyvazi, S.; Farajnia, S.; Dastmalchi, S.; Kanipour, F.; Zarredar, H.; Bandehpour, M. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update. Curr. Cancer Drug Targets 2018, 18, 857–868. [Google Scholar] [CrossRef] [PubMed]
- Gires, O.; Pan, M.; Schinke, H.; Canis, M.; Baeuerle, P.A. Expression and function of epithelial cell adhesion molecule EpCAM: Where are we after 40 years? Cancer Metastasis Rev. 2020, 39, 969–987. [Google Scholar] [CrossRef] [PubMed]
- Winter, M.J.; Nagtegaal, I.D.; van Krieken, J.H.; Litvinov, S.V. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am. J. Pathol. 2003, 163, 2139–2148. [Google Scholar] [CrossRef] [PubMed]
- Porcel, J.M. Biomarkers in the diagnosis of pleural diseases: A 2018 update. Ther. Adv. Respir. Dis. 2018, 12, 1753466618808660. [Google Scholar] [CrossRef] [PubMed]
- Andree, K.C.; van Dalum, G.; Terstappen, L.W. Challenges in circulating tumor cell detection by the CellSearch system. Mol. Oncol. 2016, 10, 395–407. [Google Scholar] [CrossRef]
- Momburg, F.; Moldenhauer, G.; Hammerling, G.J.; Moller, P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 1987, 47, 2883–2891. [Google Scholar] [PubMed]
- Proca, D.M.; Niemann, T.H.; Porcell, A.I.; DeYoung, B.R. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. Appl. Immunohistochem. Mol. Morphol. 2000, 8, 120–125. [Google Scholar] [CrossRef]
- Pan, C.C.; Chen, P.C.; Tsay, S.H.; Ho, D.M. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: A systemic immunohistochemical survey using tissue array technique. Appl. Immunohistochem. Mol. Morphol. 2005, 13, 347–352. [Google Scholar] [CrossRef]
- Latza, U.; Niedobitek, G.; Schwarting, R.; Nekarda, H.; Stein, H. Ber-EP4: New monoclonal antibody which distinguishes epithelia from mesothelial. J. Clin. Pathol. 1990, 43, 213–219. [Google Scholar] [CrossRef] [PubMed]
- Sheibani, K.; Shin, S.S.; Kezirian, J.; Weiss, L.M. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am. J. Surg. Pathol. 1991, 15, 779–784. [Google Scholar] [CrossRef] [PubMed]
- Riera, J.R.; Astengo-Osuna, C.; Longmate, J.A.; Battifora, H. The immunohistochemical diagnostic panel for epithelial mesothelioma: A reevaluation after heat-induced epitope retrieval. Am. J. Surg. Pathol. 1997, 21, 1409–1419. [Google Scholar] [CrossRef]
- Siddiqui, M.T.; Evans, H.L.; Ro, J.Y.; Ayala, A.G. Epithelioid haemangioendothelioma of the thyroid gland: A case report and review of literature. Histopathology 1998, 32, 473–476. [Google Scholar] [CrossRef] [PubMed]
- Niemiec, J.A.; Adamczyk, A.; Malecki, K.; Majchrzyk, K.; Rys, J. Relationships between immunophenotype, Ki-67 index, microvascular density, Ep-CAM/P-cadherin, and MMP-2 expression in early-stage invasive ductal breast cancer. Appl. Immunohistochem. Mol. Morphol. 2012, 20, 550–560. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.; Kim, H.S.; Cui, Z.Y.; Lee, H.S.; Ahn, J.S.; Park, C.K.; Park, K.; Ahn, M.J. Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res. 2009, 29, 1817–1822. [Google Scholar] [PubMed]
- Carneiro, F.P.; Muniz-Junqueira, M.I.; De Vasconcelos Carneiro, M.; De Araujo Oliveira, I.; Soares, A.C.; De Vargas Haar, N.; Takano, G.H.S.; De Sousa Vianna, L.M.; De Carvalho Caldas, G.; Vieira, D.L.M.; et al. Anti-EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash. Oncol. Lett. 2019, 18, 2019–2024. [Google Scholar] [CrossRef] [PubMed]
- Kobayashi, H.; Minami, Y.; Anami, Y.; Kondou, Y.; Iijima, T.; Kano, J.; Morishita, Y.; Tsuta, K.; Hayashi, S.; Noguchi, M. Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma. Virchows Arch. 2010, 457, 69–76. [Google Scholar] [CrossRef]
- Dum, D.; Taherpour, N.; Menz, A.; Hoflmayer, D.; Volkel, C.; Hinsch, A.; Gorbokon, N.; Lennartz, M.; Hube-Magg, C.; Fraune, C.; et al. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiology 2022, 89, 245–258. [Google Scholar] [CrossRef]
- Menz, A.; Gorbokon, N.; Viehweger, F.; Lennartz, M.; Hube-Magg, C.; Hornsteiner, L.; Kluth, M.; Volkel, C.; Luebke, A.M.; Fraune, C.; et al. Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors. Int. J. Surg. Pathol. 2023, 31, 927–938. [Google Scholar] [CrossRef]
- Goldenberg, D.M.; Stein, R.; Sharkey, R.M. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 2018, 9, 28989–29006. [Google Scholar] [CrossRef] [PubMed]
- Viale, G. Cytokeratin immunocytochemistry in the practice of diagnostic histopathology. Ultrastruct. Pathol. 1989, 13, 91. [Google Scholar] [CrossRef] [PubMed]
- Kononen, J.; Bubendorf, L.; Kallioniemi, A.; Bärlund, M.; Schraml, P.; Leighton, S.; Torhorst, J.; Mihatsch, M.J.; Sauter, G.; Kallioniemi, O.P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998, 4, 844–847. [Google Scholar] [CrossRef] [PubMed]
- Bubendorf, L.; Nocito, A.; Moch, H.; Sauter, G. Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies. J. Pathol. 2001, 195, 72–79. [Google Scholar] [CrossRef] [PubMed]
- Simon, R.; Mirlacher, M.; Sauter, G. Immunohistochemical analysis of tissue microarrays. Methods Mol. Biol. 2010, 664, 113–126. [Google Scholar] [CrossRef] [PubMed]
- Went, P.T.; Lugli, A.; Meier, S.; Bundi, M.; Mirlacher, M.; Sauter, G.; Dirnhofer, S. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 2004, 35, 122–128. [Google Scholar] [CrossRef] [PubMed]
- Schönberger, S.; Okpanyi, V.; Calaminus, G.; Heikaus, S.; Leuschner, I.; Nicholson, J.C.; Stoecklein, N.H.; Schneider, D.T.; Borkhardt, A. EPCAM-A novel molecular target for the treatment of pediatric and adult germ cell tumors. Genes Chromosomes Cancer 2013, 52, 24–32. [Google Scholar] [CrossRef]
- Schönberger, S.; Kraft, D.; Nettersheim, D.; Schorle, H.; Casati, A.; Craveiro, R.B.; Mohseni, M.M.; Calaminus, G.; Dilloo, D. Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines. Cancers 2020, 12, 1279. [Google Scholar] [CrossRef] [PubMed]
- Nastały, P.; Honecker, F.; Pantel, K.; Riethdorf, S. Detection of Circulating Tumor Cells (CTCs) in Patients with Testicular Germ Cell Tumors. Methods Mol. Biol. 2021, 2195, 245–261. [Google Scholar] [CrossRef]
- Cives, M.; Rizzo, F.; Simone, V.; Bisceglia, F.; Stucci, S.; Seeber, A.; Spizzo, G.; Montrone, T.; Resta, L.; Silvestris, F. Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition. Neuroendocrinology 2016, 103, 321–334. [Google Scholar] [CrossRef]
- Husain, A.N.; Colby, T.V.; Ordóñez, N.G.; Allen, T.C.; Attanoos, R.L.; Beasley, M.B.; Butnor, K.J.; Chirieac, L.R.; Churg, A.M.; Dacic, S.; et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch. Pathol. Lab. Med. 2018, 142, 89–108. [Google Scholar] [CrossRef]
- Murakami, N.; Mori, T.; Nakamura, S.; Yoshimoto, S.; Honma, Y.; Ueno, T.; Kobayashi, K.; Kashihara, T.; Takahashi, K.; Inaba, K.; et al. Prognostic value of the expression of epithelial cell adhesion molecules in head and neck squamous cell carcinoma treated by definitive radiotherapy. J. Radiat. Res. 2019, 60, 803–811. [Google Scholar] [CrossRef]
- Murakami, N.; Mori, T.; Yoshimoto, S.; Ito, Y.; Kobayashi, K.; Ken, H.; Kitaguchi, M.; Sekii, S.; Takahashi, K.; Yoshio, K.; et al. Expression of EpCAM and prognosis in early-stage glottic cancer treated by radiotherapy. Laryngoscope 2014, 124, E431–E436. [Google Scholar] [CrossRef]
- Stoecklein, N.H.; Siegmund, A.; Scheunemann, P.; Luebke, A.M.; Erbersdobler, A.; Verde, P.E.; Eisenberger, C.F.; Peiper, M.; Rehders, A.; Esch, J.S.; et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: A potential therapeutic target and prognostic marker. BMC Cancer 2006, 6, 165. [Google Scholar] [CrossRef] [PubMed]
- Matsuda, T.; Takeuchi, H.; Matsuda, S.; Hiraiwa, K.; Miyasho, T.; Okamoto, M.; Kawasako, K.; Nakamura, R.; Takahashi, T.; Wada, N.; et al. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2014, 21 (Suppl. 3), S356–S364. [Google Scholar] [CrossRef]
- Rasi Bonab, F.; Baghbanzadeh, A.; Ghaseminia, M.; Bolandi, N.; Mokhtarzadeh, A.; Amini, M.; Dadashzadeh, K.; Hajiasgharzadeh, K.; Baradaran, B.; Bannazadeh Baghi, H. Molecular pathways in the development of HPV-induced cervical cancer. EXCLI J. 2021, 20, 320–337. [Google Scholar] [CrossRef] [PubMed]
- Soysal, S.D.; Muenst, S.; Barbie, T.; Fleming, T.; Gao, F.; Spizzo, G.; Oertli, D.; Viehl, C.T.; Obermann, E.C.; Gillanders, W.E. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer. Br. J. Cancer 2013, 108, 1480–1487. [Google Scholar] [CrossRef] [PubMed]
- Went, P.; Dirnhofer, S.; Salvisberg, T.; Amin, M.B.; Lim, S.D.; Diener, P.A.; Moch, H. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am. J. Surg. Pathol. 2005, 29, 83–88. [Google Scholar] [CrossRef] [PubMed]
- Seligson, D.B.; Pantuck, A.J.; Liu, X.; Huang, Y.; Horvath, S.; Bui, M.H.; Han, K.R.; Correa, A.J.; Eeva, M.; Tze, S.; et al. Epithelial cell adhesion molecule (KSA) expression: Pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin. Cancer Res. 2004, 10, 2659–2669. [Google Scholar] [CrossRef]
- Zimpfer, A.; Maruschke, M.; Rehn, S.; Kundt, G.; Litzenberger, A.; Dammert, F.; Zettl, H.; Stephan, C.; Hakenberg, O.W.; Erbersdobler, A. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: A retrospective clinicopathological study of 948 cases using tissue microarrays. BJU Int. 2014, 114, 296–302. [Google Scholar] [CrossRef]
- Eichelberg, C.; Chun, F.K.; Bedke, J.; Heuer, R.; Adam, M.; Moch, H.; Terracciano, L.; Hinrichs, K.; Dahlem, R.; Fisch, M.; et al. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int. J. Cancer 2013, 132, 2948–2955. [Google Scholar] [CrossRef] [PubMed]
- Brunner, A.; Prelog, M.; Verdorfer, I.; Tzankov, A.; Mikuz, G.; Ensinger, C. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J. Clin. Pathol. 2008, 61, 307–310. [Google Scholar] [CrossRef] [PubMed]
- Shvarts, O.; Seligson, D.; Lam, J.; Shi, T.; Horvath, S.; Figlin, R.; Belldegrun, A.; Pantuck, A.J. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J. Urol. 2005, 173, 725–728. [Google Scholar] [CrossRef] [PubMed]
- Kaneko, M.K.; Ohishi, T.; Takei, J.; Sano, M.; Nakamura, T.; Hosono, H.; Yanaka, M.; Asano, T.; Sayama, Y.; Harada, H.; et al. Anti-EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas. Oncol. Rep. 2020, 44, 2517–2526. [Google Scholar] [CrossRef]
- Uhlen, M.; Bandrowski, A.; Carr, S.; Edwards, A.; Ellenberg, J.; Lundberg, E.; Rimm, D.L.; Rodriguez, H.; Hiltke, T.; Snyder, M.; et al. A proposal for validation of antibodies. Nat. Methods 2016, 13, 823–827. [Google Scholar] [CrossRef]
- Karlsson, M.; Zhang, C.; Méar, L.; Zhong, W.; Digre, A.; Katona, B.; Sjöstedt, E.; Butler, L.; Odeberg, J.; Dusart, P.; et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 2021, 7, eabh2169. [Google Scholar] [CrossRef]
- Lizio, M.; Harshbarger, J.; Shimoji, H.; Severin, J.; Kasukawa, T.; Sahin, S.; Abugessaisa, I.; Fukuda, S.; Hori, F.; Ishikawa-Kato, S.; et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 2015, 16, 22. [Google Scholar] [CrossRef]
- Lizio, M.; Harshbarger, J.; Abugessaisa, I.; Noguchi, S.; Kondo, A.; Severin, J.; Mungall, C.; Arenillas, D.; Mathelier, A.; Medvedeva, Y.A.; et al. Update of the FANTOM web resource: High resolution transcriptome of diverse cell types in mammals. Nucleic Acids Res. 2017, 45, D737–D743. [Google Scholar] [CrossRef]
- Consortium, G. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 2013, 45, 580–585. [Google Scholar] [CrossRef]
Figure 1.
EpCAM immunostaining of normal tissues. In the kidney, EpCAM staining was strong in distal tubuli, moderate in the visceral layer of the Bowman capsule, and weak to moderate and predominantly basolateral in proximal tubuli (A). A strong predominantly membranous EpCAM staining occurred in epithelial cells of the colorectum (B) and the gallbladder (C), as well as in the small bile ducts of the liver (D). In the stomach, EpCAM staining was the most intense in neck cells as well as in scattered small (neuroendocrine) cells within corpus and antrum glands (E). EpCAM staining was moderate to strong in prostatic epithelial cells (F) and weak to moderate in the basal cell layers of the urothelium (G). EpCAM staining was absent in the squamous epithelial cells of the skin (H). All images at 200× magnification. Insets show details at 400× magnification.
Figure 1.
EpCAM immunostaining of normal tissues. In the kidney, EpCAM staining was strong in distal tubuli, moderate in the visceral layer of the Bowman capsule, and weak to moderate and predominantly basolateral in proximal tubuli (A). A strong predominantly membranous EpCAM staining occurred in epithelial cells of the colorectum (B) and the gallbladder (C), as well as in the small bile ducts of the liver (D). In the stomach, EpCAM staining was the most intense in neck cells as well as in scattered small (neuroendocrine) cells within corpus and antrum glands (E). EpCAM staining was moderate to strong in prostatic epithelial cells (F) and weak to moderate in the basal cell layers of the urothelium (G). EpCAM staining was absent in the squamous epithelial cells of the skin (H). All images at 200× magnification. Insets show details at 400× magnification.
Figure 2.
EpCAM immunostaining in cancer. The panels show a strong predominantly membranous EpCAM staining in an adenocarcinoma of the colon (A), in an endometrioid carcinoma of ovary (B), in a Gleason 5 + 5 = 10 adenocarcinoma of the prostate (C), in a seminoma of the testis (D), a cholangiocellular carcinoma of the liver (E), a small cell neuroendocrine carcinoma of the lung (F), in a Warthin tumor of the salivary gland (G), and in an adenocarcinoma of the lung (H). Occasional weak to moderate membranous staining was found in individual cases of diffuse large cell B-cell lymphoma (I), follicular B-cell lymphoma (J), angio-immunoblastic T-cell lymphoma (K), and in a rare example of a pleural malignant (epithelioid) mesothelioma with weak to moderate EpCAM staining of a subset of tumor cells (L). EpCAM staining was lacking in most malignant (epithelioid) mesotheliomas of the pleura (M) and in hepatocellular carcinomas in the liver (N). All images are at 200× magnification except (L,M)) which are at 400× magnification.
Figure 2.
EpCAM immunostaining in cancer. The panels show a strong predominantly membranous EpCAM staining in an adenocarcinoma of the colon (A), in an endometrioid carcinoma of ovary (B), in a Gleason 5 + 5 = 10 adenocarcinoma of the prostate (C), in a seminoma of the testis (D), a cholangiocellular carcinoma of the liver (E), a small cell neuroendocrine carcinoma of the lung (F), in a Warthin tumor of the salivary gland (G), and in an adenocarcinoma of the lung (H). Occasional weak to moderate membranous staining was found in individual cases of diffuse large cell B-cell lymphoma (I), follicular B-cell lymphoma (J), angio-immunoblastic T-cell lymphoma (K), and in a rare example of a pleural malignant (epithelioid) mesothelioma with weak to moderate EpCAM staining of a subset of tumor cells (L). EpCAM staining was lacking in most malignant (epithelioid) mesotheliomas of the pleura (M) and in hepatocellular carcinomas in the liver (N). All images are at 200× magnification except (L,M)) which are at 400× magnification.
Figure 3.
Ranking order of EpCAM immunostaining in cancers. Both the percentage of positive cases (blue dots) and the percentage of strongly positive cases (orange dots) are shown.
Figure 3.
Ranking order of EpCAM immunostaining in cancers. Both the percentage of positive cases (blue dots) and the percentage of strongly positive cases (orange dots) are shown.
Figure 4.
Comparison with EpCAM in previous literature. An “X“ indicates the fraction of EpCAM-positive cancers in the present study, dots indicate the reported frequencies from the literature for comparison: red dots mark studies with ≤10 analyzed tumors, yellow dots mark studies with 11 to 25 analyzed tumors, and green dots mark studies with >25 analyzed tumors.
Figure 4.
Comparison with EpCAM in previous literature. An “X“ indicates the fraction of EpCAM-positive cancers in the present study, dots indicate the reported frequencies from the literature for comparison: red dots mark studies with ≤10 analyzed tumors, yellow dots mark studies with 11 to 25 analyzed tumors, and green dots mark studies with >25 analyzed tumors.
Table 1.
EpCAM immunostaining in human tumors.
| EpCAM Immunostaining Result | |||||||
|---|---|---|---|---|---|---|---|
| Tumor Entity | on TMA (n) | Int. (n) | Neg. (%) | Weak (%) | Mod. (%) | Strong (%) | |
| Tumors of the skin | Pilomatricoma | 35 | 28 | 89.3 | 7.1 | 0.0 | 3.6 |
| Basal cell carcinoma of the skin | 88 | 74 | 5.4 | 1.4 | 12.2 | 81.1 | |
| Benign nevus | 29 | 23 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Squamous cell carcinoma of the skin | 90 | 83 | 41.0 | 41.0 | 10.8 | 7.2 | |
| Malignant melanoma | 46 | 41 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Merkel cell carcinoma | 46 | 39 | 17.9 | 2.6 | 5.1 | 74.4 | |
| Tumors of the head and neck | Squamous cell carcinoma of the larynx | 110 | 105 | 19.0 | 23.8 | 12.4 | 44.8 |
| Squamous cell carcinoma of the pharynx | 60 | 59 | 1.7 | 22.0 | 23.7 | 52.5 | |
| Oral squamous cell carcinoma (floor of the mouth) | 130 | 127 | 23.6 | 26.8 | 19.7 | 29.9 | |
| Pleomorphic adenoma of the parotid gland | 50 | 41 | 36.6 | 19.5 | 22.0 | 22.0 | |
| Warthin tumor of the parotid gland | 49 | 45 | 0.0 | 0.0 | 6.7 | 93.3 | |
| Basal cell adenoma of the salivary gland | 15 | 14 | 0.0 | 7.1 | 57.1 | 35.7 | |
| Tumors of the lung, pleura and thymus | Adenocarcinoma of the lung | 196 | 147 | 0.0 | 0.7 | 13.6 | 85.7 |
| Squamous cell carcinoma of the lung | 80 | 51 | 2.0 | 2.0 | 7.8 | 88.2 | |
| Small cell carcinoma of the lung | 16 | 13 | 0.0 | 0.0 | 0.0 | 100.0 | |
| Mesothelioma, epithelioid | 39 | 24 | 83.3 | 12.5 | 4.2 | 0.0 | |
| Mesothelioma, biphasic | 76 | 53 | 69.8 | 17.0 | 5.7 | 7.5 | |
| Thymoma | 29 | 26 | 15.4 | 19.2 | 30.8 | 34.6 | |
| Lung, neuroendocrine tumor (NET) | 19 | 17 | 5.9 | 0.0 | 5.9 | 88.2 | |
| Tumors of the female genital tract | Squamous cell carcinoma of the vagina | 78 | 54 | 18.5 | 24.1 | 33.3 | 24.1 |
| Squamous cell carcinoma of the vulva | 130 | 116 | 7.8 | 34.5 | 24.1 | 33.6 | |
| Squamous cell carcinoma of the cervix | 129 | 117 | 1.7 | 23.9 | 28.2 | 46.2 | |
| Endometrioid endometrial carcinoma | 236 | 219 | 0.5 | 0.5 | 1.8 | 97.3 | |
| Endometrial serous carcinoma | 82 | 61 | 0.0 | 4.9 | 4.9 | 90.2 | |
| Carcinosarcoma of the uterus | 48 | 46 | 17.4 | 4.3 | 6.5 | 71.7 | |
| Endometrial carcinoma, high grade, G3 | 13 | 12 | 16.7 | 8.3 | 0.0 | 75.0 | |
| Endometrial clear cell carcinoma | 8 | 7 | 0.0 | 0.0 | 0.0 | 100.0 | |
| Endometrioid carcinoma of the ovary | 110 | 96 | 0.0 | 0.0 | 1.0 | 99.0 | |
| Serous carcinoma of the ovary | 559 | 441 | 0.2 | 0.2 | 1.1 | 98.4 | |
| Mucinous carcinoma of the ovary | 96 | 70 | 0.0 | 1.4 | 2.9 | 95.7 | |
| Clear cell carcinoma of the ovary | 50 | 43 | 0.0 | 0.0 | 2.3 | 97.7 | |
| Carcinosarcoma of the ovary | 47 | 41 | 19.5 | 7.3 | 4.9 | 68.3 | |
| Brenner tumor | 9 | 9 | 11.1 | 33.3 | 33.3 | 22.2 | |
| Tumors of the breast | Invasive breast carcinoma of no special type | 1345 | 1260 | 0.1 | 1.1 | 18.6 | 80.2 |
| Lobular carcinoma of the breast | 293 | 269 | 0.4 | 3.7 | 55.8 | 40.1 | |
| Medullary carcinoma of the breast | 26 | 26 | 0.0 | 0.0 | 19.2 | 80.8 | |
| Tubular carcinoma of the breast | 27 | 20 | 0.0 | 0.0 | 50.0 | 50.0 | |
| Mucinous carcinoma of the breast | 58 | 43 | 2.3 | 4.7 | 25.6 | 67.4 | |
| Phylloides tumor of the breast | 50 | 40 | 7.5 | 2.5 | 50.0 | 40.0 | |
| Tumors of the digestive system | Adenomatous polyp, low-grade dysplasia | 50 | 46 | 0.0 | 0.0 | 0.0 | 100.0 |
| Adenomatous polyp, high-grade dysplasia | 50 | 47 | 0.0 | 0.0 | 0.0 | 100.0 | |
| Adenocarcinoma of the colon | 1882 | 1499 | 0.1 | 0.1 | 0.5 | 99.3 | |
| Gastric adenocarcinoma, diffuse type | 176 | 160 | 0.0 | 0.0 | 10.0 | 90.0 | |
| Gastric adenocarcinoma, intestinal type | 174 | 165 | 0.0 | 1.2 | 7.3 | 91.5 | |
| Gastric adenocarcinoma, mixed type | 62 | 59 | 1.7 | 0.0 | 16.9 | 81.4 | |
| Adenocarcinoma of the esophagus | 83 | 80 | 1.3 | 3.8 | 8.8 | 86.3 | |
| Squamous cell carcinoma of the esophagus | 75 | 70 | 7.1 | 27.1 | 15.7 | 50.0 | |
| Squamous cell carcinoma of the anal canal | 89 | 80 | 16.3 | 22.5 | 26.3 | 35.0 | |
| Cholangiocarcinoma | 113 | 104 | 1.0 | 6.7 | 18.3 | 74.0 | |
| Hepatocellular carcinoma | 50 | 49 | 85.7 | 6.1 | 0.0 | 8.2 | |
| Ductal adenocarcinoma of the pancreas | 612 | 459 | 0.2 | 1.5 | 20.9 | 77.3 | |
| Pancreatic/Ampullary adenocarcinoma | 89 | 72 | 0.0 | 2.8 | 6.9 | 90.3 | |
| Acinar cell carcinoma of the pancreas | 16 | 15 | 0.0 | 0.0 | 0.0 | 100.0 | |
| Gastrointestinal stromal tumor (GIST) | 50 | 48 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Appendix, neuroendocrine tumor (NET) | 22 | 13 | 0.0 | 0.0 | 15.4 | 84.6 | |
| Colorectal, neuroendocrine tumor (NET) | 12 | 8 | 0.0 | 0.0 | 0.0 | 100.0 | |
| Ileum, neuroendocrine tumor (NET) | 49 | 44 | 0.0 | 0.0 | 4.5 | 95.5 | |
| Pancreas, neuroendocrine tumor (NET) | 97 | 89 | 0.0 | 0.0 | 5.6 | 94.4 | |
| Colorectal, neuroendocrine carcinoma (NEC) | 12 | 7 | 0.0 | 0.0 | 28.6 | 71.4 | |
| Gallbladder, neuroendocrine carcinoma (NEC) | 4 | 3 | 0.0 | 0.0 | 33.3 | 66.7 | |
| Pancreas, neuroendocrine carcinoma (NEC) | 14 | 14 | 0.0 | 7.1 | 0.0 | 92.9 | |
| Tumors of the urinary system | Non-invasive papillary urothel. ca., pTa G2 low grade | 177 | 138 | 0.0 | 18.8 | 47.1 | 34.1 |
| Non-invasive papillary urothel. ca., pTa G2 high grade | 141 | 112 | 0.0 | 16.1 | 45.5 | 38.4 | |
| Non-invasive papillary urothelial carcinoma, pTa G3 | 187 | 161 | 0.0 | 15.5 | 38.5 | 46.0 | |
| Urothelial carcinoma, pT2-4 G3 | 623 | 518 | 10.6 | 10.4 | 26.6 | 52.3 | |
| Small cell neuroendocrine carcinoma of the bladder | 20 | 20 | 25.0 | 0.0 | 0.0 | 75.0 | |
| Sarcomatoid urothelial carcinoma | 25 | 16 | 81.3 | 12.5 | 0.0 | 6.3 | |
| Clear cell renal cell carcinoma | 857 | 793 | 25.3 | 34.6 | 29.5 | 10.6 | |
| Papillary renal cell carcinoma | 255 | 232 | 5.2 | 18.1 | 29.3 | 47.4 | |
| Clear cell (tubulo) papillary renal cell carcinoma | 21 | 20 | 0.0 | 25.0 | 50.0 | 25.0 | |
| Chromophobe renal cell carcinoma | 131 | 116 | 0.9 | 3.4 | 10.3 | 85.3 | |
| Oncocytoma of the kidney | 177 | 153 | 23.5 | 37.9 | 19.6 | 19.0 | |
| Tumors of the male genital organs | Adenocarcinoma of the prostate, Gleason 3 + 3 | 83 | 83 | 0.0 | 0.0 | 10.8 | 89.2 |
| Adenocarcinoma of the prostate, Gleason 4 + 4 | 80 | 80 | 0.0 | 0.0 | 5.0 | 95.0 | |
| Adenocarcinoma of the prostate, Gleason 5 + 5 | 85 | 85 | 1.2 | 0.0 | 18.8 | 80.0 | |
| Adenocarcinoma of the prostate (recurrence) | 258 | 193 | 0.5 | 1.0 | 18.7 | 79.8 | |
| Small cell neuroendocrine carcinoma of the prostate | 19 | 16 | 0.0 | 6.3 | 0.0 | 93.8 | |
| Seminoma | 621 | 594 | 0.0 | 15.0 | 54.7 | 30.3 | |
| Embryonal carcinoma of the testis | 50 | 25 | 0.0 | 12.0 | 12.0 | 76.0 | |
| Yolk sac tumor | 50 | 32 | 0.0 | 12.5 | 9.4 | 78.1 | |
| Teratoma | 50 | 38 | 65.8 | 13.2 | 13.2 | 7.9 | |
| Squamous cell carcinoma of the penis | 80 | 79 | 32.9 | 36.7 | 13.9 | 16.5 | |
| Tumors of endocrine organs | Adenoma of the thyroid gland | 114 | 109 | 0.0 | 2.8 | 0.9 | 96.3 |
| Papillary thyroid carcinoma | 392 | 294 | 4.8 | 0.0 | 3.7 | 91.5 | |
| Follicular thyroid carcinoma | 154 | 128 | 0.8 | 0.8 | 1.6 | 96.9 | |
| Medullary thyroid carcinoma | 111 | 100 | 0.0 | 0.0 | 2.0 | 98.0 | |
| Anaplastic thyroid carcinoma | 45 | 39 | 79.5 | 10.3 | 2.6 | 7.7 | |
| Adrenal cortical adenoma | 50 | 29 | 79.3 | 17.2 | 3.4 | 0.0 | |
| Adrenal cortical carcinoma | 26 | 25 | 52.0 | 40.0 | 4.0 | 4.0 | |
| Pheochromocytoma | 50 | 50 | 94.0 | 2.0 | 4.0 | 0.0 | |
| Tumors of haemato-poetic and lymphoid tissues | Hodgkin lymphoma | 103 | 98 | 99.0 | 0.0 | 1.0 | 0.0 |
| Small lymphocytic lymphoma, B-cell type | 50 | 50 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Diffuse large B cell lymphoma (DLBCL) | 114 | 112 | 92.0 | 1.8 | 5.4 | 0.9 | |
| Follicular lymphoma | 88 | 88 | 97.7 | 1.1 | 1.1 | 0.0 | |
| T-cell non-Hodgkin lymphoma | 24 | 24 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Mantle cell lymphoma | 18 | 18 | 83.3 | 16.7 | 0.0 | 0.0 | |
| Marginal zone lymphoma | 16 | 15 | 93.3 | 6.7 | 0.0 | 0.0 | |
| Diffuse large B-cell lymphoma (DLBCL) in the testis | 16 | 16 | 87.5 | 12.5 | 0.0 | 0.0 | |
| Burkitt lymphoma | 5 | 4 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Tumors of soft tissue and bone | Tendosynovial giant cell tumor | 45 | 41 | 82.9 | 17.1 | 0.0 | 0.0 |
| Granular cell tumor | 53 | 36 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Leiomyoma | 50 | 49 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Leiomyosarcoma | 87 | 83 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Liposarcoma | 132 | 121 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Malignant peripheral nerve sheath tumor (MPNST) | 13 | 12 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Myofibrosarcoma | 26 | 26 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Angiosarcoma | 73 | 57 | 96.5 | 1.8 | 1.8 | 0.0 | |
| Angiomyolipoma | 91 | 75 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Dermatofibrosarcoma protuberans | 21 | 15 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Ganglioneuroma | 14 | 14 | 92.9 | 7.1 | 0.0 | 0.0 | |
| Kaposi sarcoma | 8 | 4 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Neurofibroma | 117 | 110 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Sarcoma, not otherwise specified (NOS) | 74 | 69 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Paraganglioma | 41 | 41 | 95.1 | 2.4 | 2.4 | 0.0 | |
| Ewing sarcoma | 23 | 14 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Rhabdomyosarcoma | 6 | 5 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Schwannoma | 121 | 115 | 99.1 | 0.9 | 0.0 | 0.0 | |
| Synovial sarcoma | 12 | 9 | 77.8 | 11.1 | 11.1 | 0.0 | |
| Osteosarcoma | 43 | 31 | 100.0 | 0.0 | 0.0 | 0.0 | |
| Chondrosarcoma | 38 | 19 | 100.0 | 0.0 | 0.0 | 0.0 | |
Abbreviation: Int.: interpretable, Neg.: negative, Mod.: moderate.
Table 2.
EpCAM immunostaining and cancer phenotype.
| EpCAM Immunostaining Result | |||||||
|---|---|---|---|---|---|---|---|
| n | Negative (%) | Weak (%) | Moderate (%) | Strong (%) | p | ||
| Invasive breast carcinoma of no special type | pT1 | 613 | 0.0 | 1.0 | 20.4 | 78.6 | 0.2200 |
| pT2 | 435 | 0.0 | 0.7 | 15.6 | 83.7 | ||
| pT3-4 | 89 | 0.0 | 0.0 | 18.0 | 82.0 | ||
| G1 | 184 | 0.0 | 1.6 | 28.3 | 70.1 | <0.0001 | |
| G2 | 597 | 0.0 | 1.2 | 20.8 | 78.1 | ||
| G3 | 396 | 0.0 | 0.0 | 9.3 | 90.7 | ||
| pN0 | 505 | 0.0 | 1.0 | 21.2 | 77.8 | 0.4295 | |
| pN+ | 366 | 0.0 | 0.8 | 17.8 | 81.4 | ||
| pM0 | 206 | 0.0 | 0.5 | 23.3 | 76.2 | 0.0006 | |
| pM1 | 109 | 0.0 | 0.0 | 7.3 | 92.7 | ||
| HER2 negative | 880 | 0.0 | 0.8 | 19.1 | 80.1 | 0.0009 | |
| HER2 positive | 121 | 0.0 | 0.8 | 6.6 | 92.6 | ||
| ER negative | 212 | 0.0 | 0.9 | 5.7 | 93.4 | <0.0001 | |
| ER positive | 741 | 0.0 | 0.5 | 19.8 | 79.6 | ||
| PR negative | 402 | 0.0 | 0.2 | 10.9 | 88.8 | <0.0001 | |
| PR positive | 592 | 0.0 | 1.0 | 21.8 | 77.2 | ||
| non-triple negative | 781 | 0.0 | 0.6 | 18.7 | 80.7 | 0.0001 | |
| triple negative | 141 | 0.0 | 0.7 | 5.7 | 93.6 | ||
| Clear cell renal cell carcinoma | ISUP 1 | 247 | 26.7 | 40.5 | 26.7 | 6.1 | 0.0010 |
| ISUP 2 | 237 | 21.9 | 31.2 | 33.8 | 13.1 | ||
| ISUP 3 | 209 | 23.9 | 32.5 | 29.2 | 14.4 | ||
| ISUP 4 | 46 | 45.7 | 17.4 | 30.4 | 6.5 | ||
| Fuhrman 1 | 41 | 24.4 | 31.7 | 34.1 | 9.8 | 0.0578 | |
| Fuhrman 2 | 440 | 24.8 | 36.4 | 29.5 | 9.3 | ||
| Fuhrman 3 | 213 | 23.0 | 31.5 | 30.5 | 15.0 | ||
| Fuhrman 4 | 54 | 42.6 | 20.4 | 31.5 | 5.6 | ||
| Thoenes 1 | 282 | 25.2 | 40.4 | 26.2 | 8.2 | 0.0005 | |
| Thoenes 2 | 395 | 22.8 | 30.1 | 33.7 | 13.4 | ||
| Thoenes 3 | 71 | 42.3 | 25.4 | 26.8 | 5.6 | ||
| UICC 1 | 346 | 25.1 | 34.4 | 29.8 | 10.7 | 0.1599 | |
| UICC 2 | 38 | 13.2 | 36.8 | 36.8 | 13.2 | ||
| UICC 3 | 92 | 18.5 | 29.3 | 34.8 | 17.4 | ||
| UICC 4 | 73 | 31.5 | 28.8 | 34.2 | 5.5 | ||
| pT1 | 451 | 25.1 | 34.4 | 30.2 | 10.4 | 0.9123 | |
| pT2 | 77 | 27.3 | 36.4 | 24.7 | 11.7 | ||
| pT3-4 | 215 | 25.6 | 31.2 | 32.6 | 10.7 | ||
| pN0 | 126 | 26.2 | 29.4 | 31.7 | 12.7 | 0.6486 | |
| pN+ | 19 | 31.6 | 26.3 | 21.1 | 21.1 | ||
| pM0 | 114 | 21.9 | 33.3 | 29.8 | 14.9 | 0.0465 | |
| pM+ | 74 | 36.5 | 27.0 | 31.1 | 5.4 | ||
| Urothelial bladder carcinoma | pTa G2 low | 138 | 0.0 | 18.8 | 47.1 | 34.1 | <0.0001 |
| pTa G2 high | 112 | 0.0 | 16.1 | 45.5 | 38.4 | ||
| pTa G3 | 163 | 0.0 | 15.5 | 38.5 | 46.0 | ||
| pT2-4 | 486 | 11.3 | 10.1 | 27.4 | 51.2 | ||
| pTa G2 low | 138 | 1.4 | 17.4 | 47.1 | 34.1 | <0.0001 | |
| pTa G2 high | 112 | 0.9 | 15.2 | 45.5 | 38.4 | ||
| pTa G3 | 163 | 1.8 | 14.7 | 38.0 | 45.4 | ||
| pT2 | 139 | 12.9 | 9.4 | 24.5 | 53.2 | ||
| pT3 | 225 | 9.3 | 12.0 | 27.1 | 51.6 | ||
| pT4 | 106 | 12.3 | 6.6 | 32.1 | 49.1 | ||
| pT2 | 139 | 12.9 | 9.4 | 24.5 | 53.2 | 0.5484 * | |
| pT3 | 225 | 9.3 | 12.0 | 27.1 | 51.6 | ||
| pT4 | 106 | 12.3 | 6.6 | 32.1 | 49.1 | ||
| G2 | 23 | 8.7 | 8.7 | 30.4 | 52.2 | 0.9686 * | |
| G3 | 447 | 11.2 | 10.1 | 27.3 | 51.5 | ||
| pN0 | 275 | 11.6 | 10.5 | 30.9 | 46.9 | 0.0582 * | |
| pN+ | 170 | 8.4 | 9.6 | 22.2 | 59.9 | ||
| Squamous cell carcinomas of different sites ** | pT1 | 266 | 12.4 | 25.9 | 20.3 | 41.4 | 0.2135 |
| pT2 | 239 | 13.0 | 29.3 | 20.5 | 37.2 | ||
| pT3 | 136 | 11.0 | 27.2 | 19.9 | 41.9 | ||
| pT4 | 128 | 14.1 | 17.2 | 15.6 | 53.1 | ||
| pN0 | 310 | 12.6 | 22.3 | 21.0 | 44.2 | 0.2559 | |
| pN+ | 307 | 8.5 | 26.4 | 18.9 | 46.3 | ||
| G1 | 25 | 48.0 | 24.0 | 8.0 | 20.0 | <0.0001 | |
| G2 | 377 | 15.6 | 33.4 | 17.5 | 33.4 | ||
| G3 | 257 | 7.8 | 19.5 | 26.8 | 45.9 | ||
* only in pT2-4 urothelial bladder carcinomas, ** oral, pharynx, larynx, esophagus, cervix, vagina, vulva, penis, anal, and lung; abbreviation: pT: pathological tumor stage, G: grade, pN: pathological lymph node status, pM: pathological status of distant metastasis, PR: progesterone receptor, ER: estrogen receptor, ISUP: International Society of Urological Pathology, UICC: Union for International Cancer Control, Fuhrman: Grading according to G.A. Fuhrman, Thoenes: Grading according to w. Thoenes.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Menz, A.; Lony, N.; Lennartz, M.; Dwertmann Rico, S.; Schlichter, R.; Kind, S.; Reiswich, V.; Viehweger, F.; Dum, D.; Luebke, A.M.; et al. Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors. Diagnostics 2024, 14, 1044. https://doi.org/10.3390/diagnostics14101044
AMA Style
Menz A, Lony N, Lennartz M, Dwertmann Rico S, Schlichter R, Kind S, Reiswich V, Viehweger F, Dum D, Luebke AM, et al. Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors. Diagnostics. 2024; 14(10):1044. https://doi.org/10.3390/diagnostics14101044
Chicago/Turabian StyleMenz, Anne, Nora Lony, Maximilian Lennartz, Sebastian Dwertmann Rico, Ria Schlichter, Simon Kind, Viktor Reiswich, Florian Viehweger, David Dum, Andreas M. Luebke, and et al. 2024. "Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors" Diagnostics 14, no. 10: 1044. https://doi.org/10.3390/diagnostics14101044
APA StyleMenz, A., Lony, N., Lennartz, M., Dwertmann Rico, S., Schlichter, R., Kind, S., Reiswich, V., Viehweger, F., Dum, D., Luebke, A. M., Kluth, M., Gorbokon, N., Hube-Magg, C., Bernreuther, C., Simon, R., Clauditz, T. S., Sauter, G., Hinsch, A., Jacobsen, F., ... Weidemann, S. (2024). Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors. Diagnostics, 14(10), 1044. https://doi.org/10.3390/diagnostics14101044
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
